Clinical Trials Logo

Toxicity Due to Chemotherapy clinical trials

View clinical trials related to Toxicity Due to Chemotherapy.

Filter by:

NCT ID: NCT02781155 Recruiting - Breast Neoplasms Clinical Trials

Limiting Chemotherapy Side Effects by Using Moxa

Start date: February 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigates whether it is feasible to teach cancer patients undergoing chemotherapy to self-administer daily moxibustion to reduce chemotherapy side effects. Moxibustion is a therapy used in traditional Chinese medicine that uses heat.

NCT ID: NCT01892852 Recruiting - Multiple Myeloma Clinical Trials

Acupuncture for Chemotherapy-induced Peripheral Neuropathy

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.

NCT ID: NCT01493011 Recruiting - Clinical trials for Non-small Cell Lung Cancer Stage IIIB

Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer

WBH&NSCLC
Start date: November 2011
Phase: N/A
Study type: Interventional

Millions of patients die of non-small cell lung cancer (NSCLC) every year. There are several methods to treat NSCLC, including surgery, chemotherapy, radiotherapy and bioimmuotherapy. Recently, hyperthermia therapy has played an important role in neoplasm therapy. It has showed some effect in NSCLC both in animal experiment and clinical practice, yet there is little literature about Whole-body Hyperthermia (WBH) with neoplasm. The investigators decides to develop this randomized contrasted multicenter clinical study to testify to the effect of chemotherapy combined with WBH to treat stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).

NCT ID: NCT01432301 Approved for marketing - Clinical trials for Toxicity Due to Chemotherapy

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to provide emergency treatment of adult and pediatric patients: - Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or - Who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous systems, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.